Stem Cell and Exosome Therapy in Pulmonary Hypertension

Pulmonary hypertension is a rare and progressive illness with a devastating prognosis. Promising research efforts have advanced the understanding and recognition of the pathobiology of pulmonary hypertension. Despite remarkable achievements in terms of improving the survival rate, reducing disease p...

Full description

Saved in:
Bibliographic Details
Published in:Korean circulation journal 2022, 52(2), , pp.110-122
Main Authors: Oh, Seyeon, Jung, Ji-Hye, Ahn, Kyung-Jin, Jang, Albert Youngwoo, Byun, Kyunghee, Yang, Phillip C, Chung, Wook-Jin
Format: Article
Language:English
Subjects:
State of the Art Review
내과학
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Pulmonary hypertension is a rare and progressive illness with a devastating prognosis. Promising research efforts have advanced the understanding and recognition of the pathobiology of pulmonary hypertension. Despite remarkable achievements in terms of improving the survival rate, reducing disease progression, and enhancing quality of life, pulmonary arterial hypertension (PAH) is not completely curable. Therefore, an effective treatment strategy is still needed. Recently, many studies of the underlying molecular mechanisms and technological developments have led to new approaches and paradigms for PAH treatment. Management based on stem cells and related paracrine effects, epigenetic drugs and gene therapies has yielded prospective results for PAH treatment in preclinical research. Further trials are ongoing to optimize these important insights into clinical circumstances.
ISSN:1738-5520
1738-5555
DOI:10.4070/kcj.2021.0191